Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Trading 43% below Graham Number ($40.34) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 21.9% with 74.4% net margin
- Revenue growing at 15% annually
Innoviva, Inc. - Common Stock (INVA) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.7 billion . Key value metrics: P/E ratio 5.8, P/B ratio 1.26, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Innoviva, Inc. - Common Stock — Fundamental Analysis Summary
Innoviva, Inc. - Common Stock (INVA) is trading 43% below its Graham Number of $40.34 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 5.8x.
On financial health, INVA shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 21.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.19.
StockPik's composite Value Score for INVA is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
INVA reports a high gross margin of 78.0% (sector average: 40.1%) and a strong operating margin of 41.3%.
INVA shows revenue growing at 15% year-over-year, with earnings growing at 1,059%.